We utilize our proprietary single cell CTC platform to develop blood based biomarkers for solid tumor indications with our pharma partners. Measurability is determined by analyzing a patient cohort for:
These ‘signatures’ can then be assessed in larger patient cohorts to help drug makers in find larger treatable patient populations for novel therapeutic trials.
All of Epic Sciences’ offerings can be included in your companion diagnostic assay to ensure the right treatment for the right patient at the right time. Request more information on CDx capabilities here: email@example.com